ReliPac (Paclitaxel) is a natural product with antitumor activity. ReliPac is a novel antimicrotubule agent that promotes assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization.
The approved indications include first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy, treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy, first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy (used in combination with cisplatin) and second-line treatment of AIDS-related Kaposi’s sarcoma.
ReliPac is obtained via a semi-synthetic process from Pacific Yew and available in three formulations i.e. 260mg / 43.4ml, 100mg / 16.7ml and 30mg / 5ml.